Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Khaled Greish

Arabian Gulf University, Manama, Kingdom of Bahrain

Title: The Use of Styrene Maleic Acid Nanomicelles Encapsulating the Synthetic Cannabinoid Analog WIN55,212-2 for the Treatment of triple negative breast Cancer

Biography

Biography: Khaled Greish

Abstract

Breast cancers are the most common cancers diagnosed in women. The therapeutic decision relies primarily on the level of expression of three protein biomarkers namely: estrogen receptor-α (ER-α), progesterone receptor (PR), and HER2. These biomarkers are essential determinants of breast cancer biology, have guided the therapeutic strategies, and predicted the response to systemic therapies.

Triple-negative breast cancers (TNBC), lacking the expression of these three biomarkers, continue to experience the highest mortality rate.

Synthetic cannabinoid WIN55,212-2 (WIN) has shown promise as an anticancer agent but causes psychoactive side-effects.

In the present study, nano-micelles of styrene maleic acid (SMA)-conjugated WIN were synthesized to reduce side-effects and increase drug efficacy against triple negative breast cancer. Pharmacokinetics studies revealed the lower brain concentrations levels of WIN formulated Nano micelles, accompanied by almost 3 folds increase in its concentration levels in cancer tissues compared to free WIN. SMA-WIN formulation reduced tumor growth with milder psychoactive side effects when compared to the free drug. Moreover, low dosage of SMA-WIN, almost devoid of psychoactive side effects, in combination with an established chemotherapeutic agent achieved therapeutic efficacy and was sufficient to reduce the tumor volume of TNBC murine cancer model drastically